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Abstract Previous studies have shown that a combination
of weight loss and ﬁsh oil supplementation reduce cardio-
vascular disease and diabetes risks by increasing adipo-
nectin and reducing triacylglyceride concentrations, while
weight loss alone signiﬁcantly improves insulin sensitivity
and reduces inﬂammation. Here, a metabolomic approach,
using a combination of
1H-Nuclear Magnetic Resonance
spectroscopy, and gas and liquid chromatography and mass
spectrometry, was employed to elucidate the metabolic
changes in blood plasma following weight loss and ﬁsh oil
supplementation. The intervention study was conducted
over 24 weeks, with 93 female subjects randomised to one
of three groups. Two groups followed a 12-week weight
loss program, followed by a 12-week weight maintenance
period and were randomised to ﬁsh or placebo oil capsules;
a control group did not follow the weight loss program and
were given placebo oil capsules. Lipid proﬁles changed
dramatically upon ﬁsh oil intake and subtly across the two
weight loss groups. While the ﬁsh oil supplementation
increased the proportion of various phospholipid species,
previously reported reductions in total triacylglycerides
(TAGs) upon ﬁsh oil intake were shown to be driven by a
reduction in a speciﬁc subset of the measured TAGs. This
remodelling of triglycerides may represent further beneﬁ-
cial effects of ﬁsh oil supplementation.
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1 Introduction
Obesity is one of the major epidemics in western societies.
In the USA obesity has doubled in adults and overweight
prevalence tripled in children and adolescents from 1980 to
2002 (Ogden et al. 2006). Obesity is correlated with a
higher risk of premature death (Manson et al. 1995), and in
particular increased risk in the development of diabetes
(Chan et al. 1994; Colditz et al. 1990), hypertension
(Stamler et al. 1978) and cardiovascular disease (CVD)
(Manson et al. 1990). Weight loss has proven to signiﬁ-
cantly improve insulin sensitivity, reduce blood pressure,
and lower the risks associated with CVD risk and type 2
diabetes. In two independent large scale intervention pro-
grams, a weight loss of 6% as part of a lifestyle modiﬁ-
cation programme reduced the risk of progression from
impaired glucose tolerance to type 2 diabetes by almost
60% (Knowler et al. 2002; Tuomilehto et al. 2001).
Long-chain n-3 polyunsaturated fatty acids (LC n-3
PUFA), either as a supplement or when consumed as oily
ﬁsh, have many beneﬁcial effects on various measures
associated with obesity and pathologies associated with the
metabolic syndrome. It has been well established that ﬁsh
oil intake lowers the total triacylglycerol concentration
considerably more than weight loss does (Harris 1996).
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DOI 10.1007/s11306-009-0161-7Furthermore, it has been suggested that dietary ﬁsh oil
supplements protect against weight gain in animals
(Kriketos et al. 2001). Fish oil has an anti-inﬂammatory
effect, as the LC n-3 PUFA have a lower inﬂammatory
response than the equivalent LC n-6 PUFA, even though
both n-3 and n-6 are precursors for inﬂammatory eicosa-
noids (James et al. 2000), providing an additional protec-
tive effect against CVD and diabetes, independent of BMI
(Browning et al. 2004; Hill et al. 2007).
The aim of this study was to examine synergistic effects
on CVD risk factors when combining weight loss with ﬁsh
oil intake. We have already reported that in this study the
weight loss intervention improved insulin sensitivity,
reduced plasma triacylglycerides and overall inﬂammation,
with additional decreases in blood plasma triglycerides and
increased adiponectin associated with ﬁsh oil supplemen-
tation (Krebs et al. 2006). In the present analysis we have
used a combined metabolomic approach to further char-
acterise the metabolic changes that accompany combined
weight loss and ﬁsh oil supplementation to better under-
stand how these interventions produce a beneﬁcial effect in
obese individuals. Metabolomics is the study of all small
molecule metabolites in a cell, tissue, organ or organism
and the changes thereof due to genetic modiﬁcation, dis-
ease or environmental stimuli (Weckwerth 2003; Grifﬁn
2004). Analysis of the changing metabolite concentrations
can then show which biological processes are involved
following a given biological stimulus. Many of the mech-
anisms by which health beneﬁts arise from weight loss or
ﬁsh oil intake are yet unclear on a metabolic level. In this
study we used
1H Nuclear Magnetic Resonance (NMR)
spectroscopy, gas and liquid chromatography and mass
spectrometry (GC-MS and LC-MS) to investigate the
changes in metabolism upon ﬁsh oil intake and weight loss.
2 Materials and methods
2.1 Study design
The study was approved by the local research ethics com-
mittee (Cambridgeshire, UK), and all subjects gave written
informed consent. A more detailed description of interven-
tion and study design has been previously published (Krebs
et al. 2006). In brief, 93 obese women completed the
24 week study. These women (average age 44.7 years; SD
13.2; range 21–69), recruited from the community, were
clinically overweight or obese (BMI[27 kg m
-2) and
hyperinsulinaemic. They were randomised to one of three
groups.Onegroupactedasacontrol(C)andweregivenonly
a placebo oil supplement, containing 2.8 g linoleic acid and
1.4 g oleic acid (provided as ﬁve 1 g oil capsules per day),
with no weight loss program (n = 26). The remaining
women were randomised to a 12-week weight loss pro-
gramme, designed to achieve a 10 % reduction in body
weight.Thiswasfollowedbya12-weekweightmaintenance
phase. Women randomised to the weight loss program were
further randomised to receive either ﬁsh oil (FO) or placebo
oil (PO) capsules. Women randomised to ﬁsh oil received
ﬁve1 gcapsulesperday(n = 35)containingpredominantly
LCn-3PUFAs(1.3 geicosapentaenoicacid(EPA)and2.9 g
docosahexaenoicacid(DHA)).Thesecondgroupweregiven
the same capsule supplement as the control group. Fasting
plasma samples were taken at 3 time points: immediately
before the study started (baseline, B), after 12 weeks
(intermediate, I) and at the end of the study after 24 weeks
(ﬁnal, F) (Fig. 1). A summary of a selection clinical data as
published earlier (Krebs et al. 2006) is given in Table 1.
2.2
1H-NMR spectroscopy of blood plasma
Plasma samples (150 ll) were diluted with 450 ll of 0.9%
NaCl in
2H2O (w/v). Spectra were acquired using a 5 mm
inverse-detection TXI probe in an 11.7 Tesla magnet
(500.3 MHz proton frequency) interfaced to a Bruker
AVANCE II? spectrometer (Bruker, Coventry, UK),
allowing the simultaneous measurement of *30 metabo-
lites which can be identiﬁed by comparison with reference
spectra. Spectra were acquired at 30C and were the sum of
64 transients acquired into 32 K data points using the 1-D
version of the noesypr1d pulse sequence: Relaxation Delay
(RD)-90-t1-90-tm-90-acquire; RD = 1.5 s, t1 = 4 ls;
TR = 2 s. The sweep width was 8,000 Hz and the water
resonance was suppressed by low power irradiation during
the mixing time (tm) of 50 ms and the relaxation delay.
35
B FO
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I FO
35
F FO
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B C
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I C
26
F C
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B PO
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I PO
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0 weeks
Inter (I)
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Fig. 1 Summary of the study design. Numbers in the boxes indicate
the number of subjects. Black boxes indicate groups taking ﬁsh oil
supplements and display the biggest differences to the other groups.
The grey box shows some differences to all others due to weight loss
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123Spectra were Fourier transformed following multiplication
by a 0.3 Hz exponential function.
Spectra were processed (phased and baseline corrected)
using the ADC/Spec Manager (Version 9.15) software. The
phase and the baseline of the spectra were manually cor-
rected. Integration of peaks was processed for regions
0.20–4.20 ppm and 5.08–9.60 ppm, excluding the water
resonance, with an integral width of 0.04 ppm, producing
213 integral buckets in total. All spectra were normalised
to total signal. The data were analysed using principal
components analysis (PCA) and partial least square dis-
criminant analysis (PLS-DA) (see below).
2.3 Blood plasma lipid extraction
Metabolite extraction was achieved using methanol, chlo-
roform and water based on the method of Bligh and Dyer
(BlighandDyer1959).Brieﬂy,150 llofbloodplasmawere
mixed with 600 ll methanol: chloroform (2:1). Samples
were sonicated for 15 min. Water and chloroform were
added (200 ll of each) and the samples centrifuged for
20 min. The resulting aqueous and organic layers were
separatedfromtheproteinpellet.Theorganiclayerwasdried
overnight in a fume food whilst the aqueous extracts were
dried using an evacuated centrifuge (Eppendorf, Hamburg,
Germany).
2.4
1H-NMR spectroscopy of aqueous blood plasma
extracts
The dried extracts of the aqueous phase were rehydrated in
600 llo fD 2O, buffered with 15 mM sodium phosphate
(pH 7.4) containing 1 mM sodium-3-(tri-methylsilyl)-
2,2,3,3-tetradeuterio-propionate (TSP; Cambridge Isotope
Laboratories, Andover, MA) as an internal standard. The
samples were analysed using the pulse sequence, NMR
spectrometer, magnet and probe described above. Spectra
were collected across 128 transients into 32 k data points
and with a 2 s inter-pulse relaxation delay. The spectra
were processed using the method described above for blood
plasma.
2.5 Gaschromatography—massspectrometry(GC-MS)
Lipids were extracted from the plasma sample using a Folch
extraction to prepare fatty acid methyl esters (Folch et al.
1957). One millilitre of methanol, containing 100 lg/ml
undecanoic acid (C11:0), was added to 200 ll sample. The
contents were vortex mixed for 1 min at 1,000 rpm, before
adding 2 ml of chloroform. The contents were mixed, as
before, for a further minute. 1 ml of 2% potassium chloride
was added and the contents were mixed as previously
described. The test-tube was transferred to a centrifuge for 5
min at 2,000 rpm at a temperature of 4C. The lower
chloroform layer was removed to a 12 9 75 mm glass tube
and evaporated to near dryness in a vacuum concentrator at
45C for 15 min. The residue was reconstituted in 3 ml of
methanol saturated with sodium hydroxide (a concentration
of *1 mol/l.) The contents were transferred to a 25 ml
tube, with stopper, and heated at 70C in a water bath for
30 min. After a brief period of cooling, to condense toxic
vapor, 4 ml of methanol containing 14% boron triﬂuoride
was added, and the contents heated at 70C for a further
Table 1 Summary of selected clinical data (SD) for the subject groups studied. For more information see (Krebs et al. 2006)
BFO
n = 35
IFO
n = 35
FFO
n = 35
BPO
n = 32
IPO
n = 32
FPO
n = 32
BC
n = 26
IC
n = 26
FC
n = 26
Weight (Kg) 92.5
(15.0)
82.6
(14.3)
82.3
(14.6)
90.8
(15.0)
79.9
(14.6)
79.5
(15.1)
90.9
(16.5)
90.6
(17.0)
91.2
(16.9)
Waist circumfence (cm) 98.7
(11.1)
91.3
(11.9)
91.1
(11.3)
99.2
(11.6)
90.7
(13.3)
90.9
(13.1)
98.3
(10.8)
98.7
(11.2)
99.3
(13.8)
BMI (Kg m
-2) 35.3
(5.6)
31.5
(5.2)
31.4
(5.4)
34.6
(5.3)
30.5
(5.3)
30.3
(5.6)
33.6
(5.7)
33.5
(5.8)
33.6
(5.9)
AUC insulin (pmol/120 min) 47333
(29191)
32909
(18858)
51534
(35657)
36390
(30071)
46396
(28390)
53460
(26538)
AUC glucose (mmol/120 min) 932
(212)
835
(126)
935
(246)
847
(243)
872
(190)
923
(236)
Triglycerides (mmol/l) 1.42
(0.79)
0.96
(0.49)
1.73
(0.71)
1.36
(0.60)
1.48
(0.99)
1.42
(0.88)
Leptin 26.7
(14.9)
16.8
(10.3)
25.9
(16.8)
13.6
(11.5)
29.1
(13.8)
26.0
(14.5)
Adiponectin (lg/ml) 10.52
(5.09)
12.85
(6.30)
11.43
(7.59)
11.21
(6.02)
9.18
(6.87)
9.71
(6.75)
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12320 min. 1 ml n-hexane was added to the tube to extract the
derivatized fatty acids (Morrison and Smith 1964). Fifteen
millilitres of de-ionized water was added to the test-tube, to
stop the reaction. The test-tube was left for a short time to
allow the contents to separate into discreet layers. The upper
n-hexane layer was removed to a fresh 12 9 75 mm glass
tube, containing a little anhydrous sodium sulphate, as
drying agent.
Samples were then injected into a Shimadzu GC-17AAF
gas chromatograph (Shimadzu Corporation, Kyoto, Japan),
ﬁtted with a SGE BPX70 column, (SGE International,
Australia) using a programmed temperature vaporisation
method. Samples were maintained at 55C for 1 min, then
increased to a temperature of 170C at a rate of 14C/min,
then to 220C at 3.5C/min, where it was held for 1 min. A
chromatogram was then obtained. Concentrations were
calculated using the internal standard (C11:0) recovery and
measured against a multi level calibration curve, plotted for
each quantiﬁed fatty acid methyl ester using Shimadzu
VP-software. The table containing the levels of 26 fatty
acids for all samples was used to perform PCA and PLS-
DA. As absolute values were used no normalisation was
necessary.
2.6 Liquid chromatography—mass spectrometry
(LC-MS)
Lipid extracts were re-dissolved in 2:1 methanol:chloro-
form and injected into a UPLC Acquity
TM (Waters, Mil-
ford, USA) with a C8 column (ACQUITY UPLC
TM BEH
C8 2.1 9 100 mm, 1.7 lm, Waters). Mobile phase A was
made up of water with 0.1% formic acid and 10 mM
ammonium acetate, while phase B was acetonitrile:iso-
propanol (5:2) with 0.1% formic acid and 10 mM ammo-
nium acetate. The analytes were eluted from the column
over 10 min with a gradient of 60–100% B followed by
2 min at 100% B and 2 min of column re-equilibration at
the starting condition 60% B. The column ﬂow rate was
600 ll/min. The UPLC was coupled to a Q-ToF micro
(Waters, Milford, USA) with a 1:1 eluent split. After every
10 sample injections a pooled sample followed by a blank
were injected in order to ensure consistent performance of
the system. The randomised sample list of extracts was run
three times, resulting in the repeating measurements being
a few days apart. MassLynx (Waters, Milford, USA) was
used to export spectra as ASCII ﬁles and further processing
was done using in-house software written in the package
IGOR PRO (WaveMetrics, Lake Oswego, Oregon, USA).
Every LC-MS ﬁle was compressed to the mass spectral
dimension by adding all retention time points at a given m/z
value. The resulting, summed mass spectra were aligned to
correct for mass drifts over the days of the analysis. Every
data point in the spectrum was kept as a variable in the
following SIMCA-P ? 11 (v11.0, Umetrics, Umea, Swe-
den) analysis if it exceeded the noise threshold in more
than 10% of all the spectra from all samples. This left 1,745
data points for each spectrum to be analysed by PLS-DA.
The spectral data for each sample was normalised to total
ion count. Re-analysis of the raw data ensured that the
extracted ion chromatograms of the signiﬁcant loadings
displayed only one peak and was not a combination of
different compounds. Typically the average coefﬁcient of
variation for LC-MS measurements was *10% of the
mean as determined by repeated injections of the pool
sample examined throughout the study. As expected, the
values for speciﬁc lipids were below this value for high
intensity peaks and higher for low abundant signals. Lipids
were identiﬁed by a combination of retention time, mass
and MS/MS measurements. No internal standard was used,
as only relative changes were studied.
2.7 Multivariate data analysis of metabolomic data
For each analytical assay the resulting data table was
imported into SIMCA-P (v11.0, Umetrics, Umea, Sweden)
for multivariate analysis by PCA and PLS-DA (an exten-
sion of PCA used for classiﬁcation). Data was normalised
to total intensity (except GC-MS) and Pareto scaled.
Identiﬁcation of major metabolic perturbations within the
pattern recognition models was achieved by analysis of
corresponding loadings plots. The parameters R
2 and Q
2
were used as measures for the robustness of a pattern
recognition model. R
2 is the fraction of variance explained
by a component, and cross validation of R
2 gives Q
2 which
reveals the fraction of the total variation predicted by a
component, it is a measure for the difference between two
(or more) groups. Typically a robust model has R
2[50%
and Q
2[40%.
For the LC-MS data the sections of the mass spectra that
had been cut out for the analysis were ﬁlled with zero
values in order to display the loadings resembling a dif-
ferential mass spectrum for a more intuitive viewing. The
peaks that contributed signiﬁcantly to the separation as
determined by the loading were then viewed as raw spectra
in order to ﬁnd the retention time of the mass that changed.
Only in a few cases, were there more than one retention
time for a speciﬁc ion, and even for these cases, the peak
responsible for classiﬁcation could be identiﬁed by visual
inspection of raw chromatograms.
3 Results
Independent of whether the samples were measured by
NMR spectroscopy, GC-MS or LC-MS, the ability to dis-
tinguish between the groups shown in Fig. 1 followed the
366 G. McCombie et al.
123same general pattern. The biggest differences in the plasma
proﬁles were associated with the intake of ﬁsh oil. The MS
based methods, showed some more subtle changes asso-
ciated with weight loss. The results obtained are discussed
in detail below for the three analytical tools used.
3.1 High resolution
1H-NMR spectroscopy
ThedominanttrendinthetotalNMRdatasetwasassociated
withthedegreeofsaturationofthetotallipidfraction.Allthe
samplescollectedfromwomentakingﬁshoilhadanincrease
in the resonance intensity at 5.24–5.32 ppm, corresponding
to CH=CH, and 2.72–2.80 corresponding to CH=CH–CH2–
CH=CHmoieties.Equally,theintegralregionsbetween1.24
and 1.32 ppm, where the CH2–CH2–CH2 resonances asso-
ciated with saturation in fatty acids contribute to the spectra,
werereducedintheﬁshoilgroupsrelativetoallothergroups
(Fig. 2).Nodifferencesassociatedwithweightloss,couldbe
found in the plasma NMR dataset.
As the lipid resonances overlap with aqueous metabo-
lites, for example the 1.24–1.32 ppm region overlaps with
a doublet from lactate, we examined aqueous extracts of
the blood plasma to examine whether differences
associated with aqueous metabolites and not lipid species
were responsible for the classiﬁcations. However, analysis
of the entire dataset demonstrated no separation for any of
the groups, indicating that all classiﬁcations were associ-
ated with lipid species (data not shown). This conclusion
held for all regions of the NMR spectrum where resonances
from low molecular weight metabolites were obscured by
broad lipid resonances. Thus, future analysis focussed on
the lipid fraction.
3.2 GC-MS of total fatty acid content of blood plasma
As the NMR data suggested that the largest differences
between the groups are associated with lipid moities, in
the next stage of the analysis, the total fatty acid proﬁles
were measured as fatty acid methyl esters (FAMEs) using
GC-MS. This data has been previously presented using a
univariate statistical approach (Krebs et al. 2006). Two
way comparisons were made between the groups using
pattern recognition methods. The most robust PLS-DA
models of the data were built between IFO or FFO and
any other group, indicating that ﬁsh oil supplementation
dominated the measured changes. However, more subtle
ppm
ppm ppm
ppm
1.8 1.6 1.4 1.2 1.0 0.8
5.8 5.6 5.4 5.2 5.0
3.6 3.4 3.2 3.0 2.8 2.6
5 43 2 1
Subject 44 baseline (BFO)
Subject 44 12 weeks (IFO)
Subject 44 baseline (BFO)
Subject 44 12 weeks (IFO)
Fig. 2 Two NMR spectra of a subjects’ plasma at baseline (without ﬁsh supplementation; BFO) and after 12 weeks (with ﬁsh oil
supplementation; IFO). The increasing number of double bonds in the lipid signals was the only clear change in the NMR spectra of the plasma
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123differences due to weight loss could be detected between
IPO or IFO and IC. The robustness (Q
2) was used to assess
the validity of the models. While models with a Q
2[0.08
are considered statistically signiﬁcant, only those with
Q
2[0.4 robustly predict class membership for individual
samples left out of the model. In these comparisons BFO/
IFO had a Q
2 of 0.63, while BPO/IPO had a Q
2 of only
0.53, demonstrating that feeding ﬁsh oil had the biggest
impact on the lipid proﬁle while weight loss produced a
less robust model.
To understand the metabolic changes that were
responsible for these classiﬁcations the loadings of the
PLS-DA plots for the GC-MS data were analysed.
Figure 3a shows the composition of the ﬁsh- and placebo
oil used in this study, with the fats administered as tria-
cylglycerols (TAGs), while Fig. 3b shows a typical FAME
proﬁle from a subject at baseline. The most abundant fatty
acids in plasma are 16:0, 18:1n-9c and 18:2n-6c and these
are also the main components of the placebo oil, in order to
have the smallest overall effect on the lipid proﬁle in the
group receiving the placebo oil. The ﬁsh oil supplemen-
tation resulted in signiﬁcant increases in the fatty acids
supplied in the supplement in the FO group (Fig. 3c, d;
Table 2). However, the fatty acids C22:5 (both n3 and n6
species) were affected by both weight loss (decreased in
IPO vs. BPO) and ﬁsh oil supplementation (increased in
IFO vs. BFO). While the fatty acid was the third most
abundant fatty acid constituent in ﬁsh oil (Fig. 3a), weight
loss had a greater effect, and hence an overall (but smaller)
decrease was seen between BFO and IFO compared with
BPO and IPO. However, the seemingly signiﬁcant change
of 10:0 (Fig. 3d) was discarded because it was too close to
the detection limit to be reliably quantiﬁed.
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Fig. 3 Fatty acid methyl ester (FAME) analysis with the most
common fatty acids highlighted in panels A, B and D. a Fatty acid
composition of the ﬁsh (h)—and placebo oil (j) capsules measured
by GC-MS. b Typical FAME proﬁle of blood plasma from a subject.
The shown sample is from the BPO group. c Score plot of PLS-DA
model between the baseline and 12-week time point of the ﬁsh oil
group (BFO vs. IFO; Q
2 = 0.63, R
2 = 0.68. d Loading plot driving
the separation shown in c
Table 2 Signiﬁcant changes in FAMEs, with the intervention cause
and direction of the changes
Fatty acid Change in dataset
C16:1n-9c
C18:1n-9c
C18:3n-3
C20:3n-3
Reduced with ﬁsh oil supplementation
C20:5n-3
C22:6n-3
C22:5
Increased with ﬁsh oil supplementation
C22:5 Reduced with weight loss at 12 & 24 weeks
C20:1n-9 Reduced with weight loss at 12 weeks
C18:1n-7c Increased with weight loss (in placebo group only)
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1233.3 LC-MS
One limitation of understanding fatty acid metabolism
through GC-MS is that the approach measures total fatty
acid content, rather than what lipid species might contrib-
ute to these changes. LC-MS was performed to address this
question. Figure 4 illustrates a typical 2D LC-MS run (a)
and the reproducibility of the method used (b). The peaks
at higher mass and later retention time are from the tria-
cylglycerides (TAGs) while the cluster of peaks at earlier
retention time and lower mass are from the polar phos-
pholipids (a). The chromatography time used in these runs
was a compromise between the need to resolve as large a
number of lipid species during the assay and a need to
minimise the run time to allow data acquisition in a rea-
sonable timescale. Panel b demonstrates the reproducibility
of the LC-MS measurements with a subset of spectra from
the BPO group. A subset of the samples from the BPO
group, each injected three times, are plotted in a PCA
scores plot. Repeats of every sample were given the same
symbol, demonstrating that the biological variation is
clearly greater than the variation between technical repeats.
From both visual inspection and pattern recognition
analysis, as with the GC-MS data, the main differences in
the lipid proﬁle was due to the ﬁsh oil supplementation and
only more subtle differences were found due to weight loss.
A PLS-DA scores plot of all 3 groups at the intermediate
time point show minor overlap between the IFO and IPO/
IC groups and major overlap between the IPO and IC
groups (supplementary Fig. 1).
To better deﬁne the metabolic differences between
groups two-way comparisons for all groups were carried
out using PLS-DA. Figure 5 shows an example of a PLS-
DA model (Q
2 = 0.85; R
2 = 0.90—the highest Q
2 of all
2-way models) between IFO and BPO with scores (panel a)
and the loadings (panel b) plot including the standard
deviation of the loadings (grey lines). The Q
2 measure was
used to determine how dissimilar two groups were across
the whole dataset. Figure 6 summarises all possible pair
wise comparisons for the LC-MS dataset by PLS-DA. The
most robust models, and hence largest biochemical dif-
ferences, between groups were associated with ﬁsh oil
supplementation (any group vs. IFO and FFO). However,
more minor effects were associated with short term weight
loss, and no signiﬁcant differences (within our deﬁnition of
model robustness) were found for the control group (BFO
vs. IFO Q
2 = 0.72; BPO vs. IPO Q
2 = 0.40; BC vs. IC
Q
2 = 0.15).
The PLS-DA plots were validated by randomly permu-
tating the value of Y and comparing the Q
2 to the true
value. In the case of the comparison between BC and IPO
(Q
2 = 0.5) the resulting regression line through the true
and false Q
2 s has an offset of -0.3 demonstrating the
robustness of the model (supplementary Fig. 2). Similar
results were achieved with all models considered signiﬁ-
cant (Q
2[0.4) ensuring there was no over ﬁtting of the
data.
Further conﬁdence in the models was gained because
each mass spectral peak consists of several data points
creating redundancy for each lipid species. These multiple
data points consistently were identiﬁed together in the
loadings plots (Fig. 5b). The lipids responsible for classi-
ﬁcation above a set threshold (eight times the noise level)
and with error bars\±40% were analysed in more detail
using a combination of tandem MS, retention time and
database searching. Careful evaluation of all comparisons
yielded a list of signals that change signiﬁcantly and could
be attributed either to ﬁsh oil intake or diet intervention
(Table 3).
In terms of the class of lipid species affected the largest
decreases on ﬁsh oil supplementation were associated with
TAGs, suggesting that this class of lipids had decreased in
general, which has been published before (Harris 1996;
Krebs et al. 2006). This was conﬁrmed by biochemical
assay for total TAG concentration (e.g. P = 5.13 9 10
-4
for BFO and IFO comparison, according to a Student
t-test). However, some of the high intensity TAG signals,
such as 52:3 and 52:2, in the raw data did not change
signiﬁcantly with ﬁsh oil intake indicating a remodelling of
this class of lipid as well as an overall reduction. following
ﬁsh oil feeding.
4 Discussion
In this study we have employed a combined NMR spec-
troscopy, GC-MS and LC-MS metabolomic analysis of
blood plasma in order to identify metabolic changes asso-
ciated with ﬁsh oil supplementation, weight loss and the
interaction between these two interventions. Currently no
single analytical tool will provide a complete analysis of
the metabolome and our strategy for open proﬁling is to use
a combination of analytical devices. Although being the
technique of least sensitivity,
1H-NMR spectroscopy was
both rapid (*12 min per sample) and reproducible.
However, because of the chemical nature of lipid species
1H-NMR spectroscopy provides poor discrimination
between individual fatty acids. However, GC-MS provides
a robust method for distinguishing changes in total fatty
acid concentration in samples, but analysis times are longer
(*30 min) and require prior derivatisation. LC-MS is
capable of examining intact lipids directly. While assay
times in this study were *15 min per sample, the lower
reproducibility of this approach compared with the other
two analytical tools necessitated the analysis of samples in
triplicate.
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123GC-MS is a robust method for fatty acid analysis and is
often used for metabolomics. It does however, when
applied to lipid analysis, only measure the total fatty acid
composition. The information on the origin of the fatty
acids is lost during the derivatisation process. LC-MS on
the other hand measures intact lipid species but the infor-
mation on the exact fatty acid composition is harder to
determine. However, both techniques may be used com-
plimentarily to maximise the information obtainable from
the lipid fraction.
The data obtained by NMR spectroscopy demonstrated
two important pieces of information that determined the
direction of the mass spectrometric analyses. Firstly, no
difference was found between samples for the aqueous
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Fig. 4 a Example of the LC-MS measurement of a lipid extract from
plasma. b PCA plot demonstrating the reproducibility of the LC-MS
data. Each symbol represents a sample from the baseline of the
placebo oil group and was injected three times. The technical repeats
cluster together indicating that the variation between the samples is
much bigger than the technical variation even if the samples were
acquired over several days
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123metabolites but clear differences were detected for the
whole plasma containing lipids. Secondly, the differences
in the plasma lipids were, not surprisingly, associated with
the degree of saturation in the fats of the groups supple-
menting their diet with ﬁsh oil. As there is signiﬁcant
resonance overlap between different fatty acids/lipid spe-
cies further analyses were performed by mass spectrometry
to determine the biochemical changes associated with ﬁsh
oil supplementation.
The total reduction of TAGs upon increased intake of n-
3 PUFAs that was found in these data is well established in
the literature (Harris 1996; Krebs et al. 2006). However, we
demonstrate in the present study that a remodelling of the
TAG species has occurred. While the majority of the
TAG(48:x where x signiﬁes the number of double bonds)
and TAG(50:x) decreased in concentration, the low abun-
dance TAG(46:x) and TAG(56:x) and the high abundance
TAG(52:x) and TAG(54:x) do not, with the exception of
TAGs containing ﬁve unsaturated bonds across all three
fatty acids.
The diverse range of changes detected in the lipid proﬁle
by LC-MS conﬁrm previous literature reports where others
have used LC-MS to study either animal models or patients
with obesity, type 2 diabetes and the metabolic syndrome.
Yetukuri and colleagues used LC-MS to study liver tissue
of ob/ob mice and compared this to tissue from wild type
animals (Yetukuri 2007). The authors found a general
increase of short chain TAGs in ob/ob but not long chain
ones. Speciﬁcally, TAG(48:2), TAG(48:1) and TAG(50:2)
are decreased with ﬁsh oil supplementation in our study
and increased in ob/ob mouse liver lipid proﬁles (Yetukuri
2007). Another study from the same group (Medina-Go-
mez 2007) identiﬁed a major decrease of TAG(48:2) in the
POKO mouse (a double gene deletion of the leptin receptor
and PPARc) and a minor decrease in white adipose tissue
(WAT) from ob/ob mice. In skeletal muscle TAG(48:2)
and TAG(48:1) were decreased in the POKO mouse but not
in ob/ob. All of these mentioned TAGs were also found to
be altered in our study, demonstrating that the triglyceride
pool is selectively modulated by obesity, type 2 diabetes
and dietary intervention.
Another study, where subjects with metabolic syndrome
were subjected to a 33-week diet intervention study, has
shown a similar rearrangement of chain length in plasma
TAGs (Schwab et al. 2008). The authors demonstrate a
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123decrease in short chain saturated fatty acids and that this
change is correlated to insulin sensitivity. Despite the low
sample size this study did beneﬁt from a wider lipidomic
coverage, probably rendering the analysis more sensitive to
lipid remodelling. However our study showed clearly that
weight loss with the addition of dietary ﬁsh oil supple-
mentation causes a large rearrangement of the lipid tri-
glyceride pool.
The complimentary nature of a combined GC-MS and
LC-MS approach was evident from the cross correlation of
the two data sets. For example, the decrease in the fatty
acids 18:3 and 20:3 with ﬁsh oil supplementation as
determined by GC-MS is consistent with the decrease of
PC(36:3) and PC(38:3) if one assumes that one of the fatty
acids in these species is the highly abundant palmitate
(16:0—Fig. 3b). Neither of these fatty acids correlates with
any TAG reduction indicating that the decrease in 18:3 and
20:3 fatty acids preferentially affect PC lipids rather than
triglycerides. This suggests that LC n-3 PUFA increase the
metabolism of short chain n-3 PC.
As shown by the LC-MS data, the wide variety of lipid
types (phospholipids and TAG/DAG) that increase with
ﬁsh oil supplementation all have a high degree of unsatu-
ration. This is most likely due to the effect of lipid syn-
thesis with the supplemented n-3 PUFA. Unfortunately,
one complication in interpreting the results produced in this
study is that it was not possible to discriminate between
effects associated with ﬁsh oil supplementation alone and
the combined action of ﬁsh oil and weight loss as the study
design did not include a group supplemented with ﬁsh oil
in the absence of weight loss (Krebs et al. 2006). The
inclusion of this group would have allowed separation of
the weight loss and ﬁsh oil effects. Hence, it remains
unclear as to which of the changes are due to the ﬁsh oil
intake alone and which of them may be due to a synergistic
weight loss/ﬁsh oil supplementation effect.
One of the lipids with a relatively high degree of satu-
ration which increased in concentration in the ﬁsh oil
supplemented group was SM(38:2). Conversely the con-
centrations of SM(42:1) and SM(42:2) have been found to
Table 3 Summary of signiﬁcant changes in LC-MS peaks between groups
Loading mass (M?H
?)R T I D
Increased with ﬁsh oil supplementation 688.8 7.56 DAG(40:10)
780.7 4.83 PS(36:6)o rPC(36:5)
806.6 5.04 PC(38:6)
808.7 5.24 PS(36:6)o rPC(36:5)
813.7 6.22 SM(38:2)
834.7 5.49 PS(40:7)o rPC(40:6)
920.8 7.72 TAG(56:8)
894.8 7.66 TAG(54:7)
a
731.8 5.31 PA(38:1)
a
714.8 7.61 DAG(42:11)
a
Decreased with ﬁsh oil supplementation 784.7 5.31 PC(36:3)
812.7 5.76 PC(38:3)
820.9 7.84 TAG(48:2)
822.9 7.99 TAG(48:1)
846.9 7.85 TAG(50:3)
848.8 8.01 TAG(50:2)
850.9 8.16 TAG(50:1)
870.9 7.72 TAG(52:5)
898.9 7.91 TAG(54:5)
732.8 5.32 PS(32:2)o rPC(32:1)
a
794.9 5.49 PE(40:5)
a
Increased with weight loss (WLPO only) 703.7 4.78 SM(30:1)
766.8 5.38 PE(38:5)
Decreased with weight loss only 878.8 8.31 TAG(52:1)
Note: Tentative (low abundance/no MS/MS) or ambiguous identiﬁcations are in italics
TAG triacylglycerol, DAG diacylglycerol, PC glycerophosphatidyl choline, PS glycerophosphoserine, PE glycerophospho ethanolamine,
PA glycerophospatydic acid, SM sphingomyeline
a Denotes signals at very low abundance in the raw data
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123decrease in ob/ob mouse liver (Yetukuri 2007). Thus, this
increase in SM may be a beneﬁcial effect of ﬁsh oil feeding
although the exact mechanism remains to be elucidated
underlying the complexity of the data set obtained by
LC-MS lipidomics.
The changes observed based on weight loss alone
include the increase in concentration of SM(30:1) con-
taining very short chained fatty acids. In addition a
decrease in TAG(52:1) was detected. This might suggest a
decrease in speciﬁc TAGs rather than the general reduction
of short chain species we observe with the ﬁsh oil sup-
plemented groups. However, these were some of the few
biological changes associated with weight loss and placebo
oil detected across this study, in part because of the study
design and the very large changes associated with dietary
intervention which dominate the dataset.
The chromatogram peak representing fatty acid 22:5 (a
sum of n-6 and n-3 fatty acids) displayed an interesting
behaviour as determined by GC-MS. Despite it being the
third most abundant fatty acid in the ﬁsh oil supplemen-
tation (Fig. 3a) it decreased in the comparison between
BFO and IFO (Fig. 3c, d) after ﬁsh oil supplementation.
However, this fatty acid decreased in the weight loss group
at 12 and 24 weeks with higher signiﬁcance as determined
by the relative intensity of the loadings. This leads to the
conclusion, that weight loss decreases 22:5 but that this
reduction is masked slightly by the supplement of ﬁsh oil in
the diet, so that although weight loss results in an overall
decrease between the BFO and IFO group this is not as
large as that detected between BPO and IPO. The decrease
in the fatty acid is also reﬂected in the decrease of serum
TAG(54:5) which might well be made up of 2 16:0 (one of
the most common fatty acids—Fig. 3b) and one 22:5 fatty
acids. TAG(54:5) therefore is an exception of a decreasing
serum TAG with more than 52 carbons. Interestingly,
TAG(54:5) has been reported to decrease in WAT in ob/ob
mice and increase in the double knock out POKO in the
same tissue as compared to wild type (Medina-Gomez
2007). Assuming that TAG(54:5) contains fatty acid 22:5
this means there is an inverse correlation of the amount of
22:5 in WAT and serum. 22:5 is synthesised from 18:2.
The last step of the synthesis takes place in the peroxi-
somes (Innis 2003; Innis et al. 2004). The decrease in ob/ob
WAT but increase in the POKO mouse suggests that
PPARc promotes the mobilisation of 22:5 from adipose
tissue. In respect to the study investigated here this sug-
gests that weight loss increases the PPARc activity in WAT
cells.
This result also illustrates the difﬁculty of ultimately
identifying the exact lipid composition in the samples. This
holds particularly true for low abundance lipid species. The
number of structural isomers within lipids is enormous and
the reliable separation and quantiﬁcation of all the lipid
species is in the centre of active, ongoing research. With
time this will lead to more assertive assignments and ulti-
mately improved biological interpretation of disease pro-
cesses in the future.
Surprisingly there were also detectable differences
between groups that were planned to be similar. For
instance the two baseline groups BPO and BFO (Fig. 6)
have a relatively high Q
2 of almost 0.4. This indicates the
difﬁculty of randomising people even with *30 subjects in
each group. Furthermore, such studies are also affected by
human behaviour. Being part of a study as a control group
is most likely going to inﬂuence the behaviour of the
control group subjects. Indeed we would expect this effect
to be most pronounced before samples are taken. This
suggests that blood plasma based studies should perhaps be
considered alongside material with a slower changing
proﬁle such as red blood cells or adipose tissue.
5 Conclusions
This study investigated ﬁsh oil supplemented diet in
combination with weight loss by a variety of metabolomic
methods. The ﬁsh oil supplementation was found to have
the largest effect on plasma metabolic proﬁles. Further-
more only the lipid fraction seemed to be affected as was
determined by high resolution
1H-NMR spectroscopy. Fish
oil supplementation in conjunction with weight loss was
found to reduce the total serum TAG content by selectively
reducing the short chain fatty acids. Weight loss caused a
reduction in the fatty acid 22:5, although this fatty acid was
also increased by ﬁsh oil supplementation relative to
individuals receiving placebo oil. Overall, these results
demonstrate the selective modulation of blood plasma
TAGs by ﬁsh oil supplementation.
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